{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"247"}],"title":"Relapsed (event)"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Died (event)"},{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"36"}],"title":"Censored, follow-up ended at the time of Primary Completion Date"},{"measurements":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"149"}],"title":"Censored, follow-up ongoing at the time of Primary Completion Date"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"The first appearance of local/distant metastasis or mortality due to disease recurrence or toxicity were used as events. Censoring was performed using the date of last assessment for those who were alive without local/distant metastasis or new primary melanoma at the time of analysis. FFR was censored if patients died from causes other than melanoma or treatment-related toxicity at the date of death.","groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"OG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"OG001","title":"Dabrafenib and Trametinib Placebos"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population","reportingStatus":"POSTED","timeFrame":"Approximately 4 years","title":"Percentage of Participants With Freedom From Relapse (FFR) Events","type":"SECONDARY","unitOfMeasure":"Participants"}